<code id='ABB33BB427'></code><style id='ABB33BB427'></style>
    • <acronym id='ABB33BB427'></acronym>
      <center id='ABB33BB427'><center id='ABB33BB427'><tfoot id='ABB33BB427'></tfoot></center><abbr id='ABB33BB427'><dir id='ABB33BB427'><tfoot id='ABB33BB427'></tfoot><noframes id='ABB33BB427'>

    • <optgroup id='ABB33BB427'><strike id='ABB33BB427'><sup id='ABB33BB427'></sup></strike><code id='ABB33BB427'></code></optgroup>
        1. <b id='ABB33BB427'><label id='ABB33BB427'><select id='ABB33BB427'><dt id='ABB33BB427'><span id='ABB33BB427'></span></dt></select></label></b><u id='ABB33BB427'></u>
          <i id='ABB33BB427'><strike id='ABB33BB427'><tt id='ABB33BB427'><pre id='ABB33BB427'></pre></tt></strike></i>

          hotspot

          hotspot

          author:Wikipedia    Page View:59
          illustration of one blue dna strand
          Adobe

          The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

          Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

          advertisement

          Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Tori Bowie and the unacceptable rates of Black maternal death
          Tori Bowie and the unacceptable rates of Black maternal death

          AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

          read more
          Unique patient identifier: Experts argue the benefits, pitfalls
          Unique patient identifier: Experts argue the benefits, pitfalls

          Therehasbeenlong-standingdebateintheUSoverwhethertoimplementauniquepatientidentifiersystem.EvanVucci

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          AI gets buy

          MikeReddyforSTATDavidReesecallsita“hingemoment”—theturningpointwhenbiotechandbigtechmergetoattackhum